Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963969 | 1.00 | KMT2A (0.37) | KMT2AHTTMEN1POLBHSD17B10 | |
| SCHEMBL30161448 | 1.00 | KMT2A (0.37) | KMT2AHTTMEN1POLBHSD17B10 | |
| SCHEMBL21963842 | 0.81 | MAPT (0.38) | HTTPOLBKCNA5ALDH1A1GAA | |
| SCHEMBL24923428 | 0.81 | MAPT (0.38) | HTTPOLBKCNA5ALDH1A1GAA | |
| SCHEMBL22129298 | 0.77 | ADRB2 (0.33) | HTTHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL22129299 | 0.77 | ADRB2 (0.33) | HTTHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL22129305 | 0.77 | ADRB2 (0.33) | HTTHSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL19836479 | 0.74 | KMT2A (0.50) | KMT2AHTTMEN1POLBKDM4E | |
| SCHEMBL28609306 | 0.73 | KMT2A (0.40) | KMT2AHTTMEN1POLBHSD17B10 | |
| SCHEMBL22011048 | 0.73 | HSD17B10 (0.42) | KMT2AHTTMEN1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2022268890-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | KMT2A 3401/4885HTT 2003/4885MEN1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.